{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Li F"],"pubmed_abstract":["Neutralizing antibodies exert a potent inhibitory effect on viral entry; however, they are less effective in therapeutic models than in prophylactic models, presumably because of their limited efficacy in eliminating virus-producing cells via Fc-mediated cytotoxicity. Herein, we present a SARS-CoV-2 spike-targeting bispecific T-cell engager (S-BiTE) strategy for controlling SARS-CoV-2 infection. This approach blocks the entry of free virus into permissive cells by competing with membrane receptors and eliminates virus-infected cells via powerful T cell-mediated cytotoxicity. S-BiTE is effective against both the original and Delta variant of SARS-CoV2 with similar efficacy, suggesting its potential application against immune-escaping variants. In addition, in humanized mouse model with live"],"journal":["Communications biology"],"pagination":["592"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10234585"],"repository":["biostudies-literature"],"pubmed_title":["A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo."],"pmcid":["PMC10234585"],"pubmed_authors":["Han P","Xie Y","Li F","Zhang H","Jiang S","Wang H","Li M","Yang X","Lu L","Su S","Dai Q","Qi X","Zhang X","Fan L","Liang J","Lin H","Wang W","Wang X","Xu W","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo.","description":"Neutralizing antibodies exert a potent inhibitory effect on viral entry; however, they are less effective in therapeutic models than in prophylactic models, presumably because of their limited efficacy in eliminating virus-producing cells via Fc-mediated cytotoxicity. Herein, we present a SARS-CoV-2 spike-targeting bispecific T-cell engager (S-BiTE) strategy for controlling SARS-CoV-2 infection. This approach blocks the entry of free virus into permissive cells by competing with membrane receptors and eliminates virus-infected cells via powerful T cell-mediated cytotoxicity. S-BiTE is effective against both the original and Delta variant of SARS-CoV2 with similar efficacy, suggesting its potential application against immune-escaping variants. In addition, in humanized mouse model with live","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-07-14T20:07:57.292Z","creation":"2025-02-19T04:46:07.981Z"},"accession":"S-EPMC10234585","cross_references":{"pubmed":["37264086"],"doi":["10.1038/s42003-023-04955-3"]}}